- Stocks
- Healthcare
- NASDAQ: HRTX

Price (delayed)

$12.89

Market cap

$1.31B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.51

Enterprise value

$1.28B

The debt has declined by 3.8% year-on-year

The quick ratio has contracted by 50% YoY and by 17% from the previous quarter

The equity has declined by 46% year-on-year and by 17% since the previous quarter

What are the main financial stats of HRTX

Market
Valuations
Earnings

Shares outstanding

101.83M

Market cap

$1.31B

Enterprise value

$1.28B

Price to earnings (P/E)

N/A

Price to book (P/B)

6

Price to sales (P/S)

14.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

15.34

Revenue

$83.26M

EBIT

-$230.05M

EBITDA

-$227.08M

Free cash flow

-$198.48M

Per share
Balance sheet
Liquidity

EPS

-$2.51

Free cash flow per share

-$2.17

Book value per share

$2.15

Revenue per share

$0.91

TBVPS

$3.4

Total assets

$310.93M

Total liabilities

$114.71M

Debt

$24.43M

Equity

$196.23M

Working capital

$171.37M

Debt to equity

0.12

Current ratio

2.7

Quick ratio

2.03

Net debt/EBITDA

0.16

Margins
Efficiency
Dividend

EBITDA margin

-272.7%

Gross margin

58.2%

Net margin

-274.2%

Operating margin

-273.3%

Return on assets

-61.4%

Return on equity

-88.3%

Return on invested capital

-108%

Return on capital employed

-109.5%

Return on sales

-276.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Heron Therapeutics stock price performed over time

Intraday

-1.15%

1 week

0.16%

1 month

-21.5%

1 year

-23.04%

YTD

-39.11%

QTD

-16.95%

How have Heron Therapeutics's revenue and profit performed over time

Revenue

$83.26M

Gross profit

$48.48M

Operating income

-$227.54M

Net income

-$228.31M

Gross margin

58.2%

Net margin

-274.2%

The net margin has dropped by 98% year-on-year and by 7% since the previous quarter

HRTX's operating margin has dropped by 92% year-on-year and by 6% since the previous quarter

HRTX's gross profit is down by 41% year-on-year and by 8% since the previous quarter

HRTX's revenue is down by 40% year-on-year and by 6% since the previous quarter

What is Heron Therapeutics's growth rate over time

What is Heron Therapeutics stock price valuation

P/E

N/A

P/B

6

P/S

14.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

15.34

Heron Therapeutics's EPS has decreased by 11% YoY

The equity has declined by 46% year-on-year and by 17% since the previous quarter

The P/B is 36% lower than the 5-year quarterly average of 9.5 and 2.1% lower than the last 4 quarters average of 6.2

HRTX's price to sales (P/S) is 73% less than its 5-year quarterly average of 53.8 and 9% less than its last 4 quarters average of 15.8

HRTX's revenue is down by 40% year-on-year and by 6% since the previous quarter

How efficient is Heron Therapeutics business performance

Heron Therapeutics's return on sales has shrunk by 94% YoY and by 7% QoQ

The ROIC has plunged by 63% YoY and by 16% from the previous quarter

Heron Therapeutics's ROE has plunged by 55% YoY and by 17% from the previous quarter

HRTX's ROA is down by 43% YoY and by 12% QoQ

What is HRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HRTX.

How did Heron Therapeutics financials performed over time

Heron Therapeutics's total assets is 171% higher than its total liabilities

The quick ratio has contracted by 50% YoY and by 17% from the previous quarter

The current ratio has contracted by 40% YoY and by 12% from the previous quarter

The debt is 88% smaller than the equity

The debt to equity has soared by 71% year-on-year and by 20% since the previous quarter

The equity has declined by 46% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.